Home
Journals
Focus
Videos
Language
English
中文简体
Sign in
All
Title
Author
Year
Keyword
Text
Search
Journals
Engineering
13
Strategic Study of CAE
2
Frontiers of Chemical Science and Engineering
4
Frontiers of Information Technology & Electronic Engineering
1
Frontiers of Medicine
77
Selected
Sort by
select
Time desc
Time asc
Export
EndNote
RefWorks
NoteExpress
BibTe
Ref Manager
ProCite
Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies
CTLA-4, PD-1, PD-L1, immune checkpoint blockade (ICB), metabolic reprogramming, combined tumor therapeutic strategies
Frontiers of Medicine
2023.17(5) 805-822
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models
BGB-A445, OX40, agonistic antibody, OX40L noncompetitive
Frontiers of Medicine
2023.17(6) 1170-1185
Minimal residual disease in solid tumors: an overview
MRD, solid tumor, CTC, ctDNA
Frontiers of Medicine
2023.17(4) 649-674
Extracellular vesicle-carried GTF2I from mesenchymal stem cells promotes the expression of tumor-suppressive FAT1 and inhibits stemness maintenance in thyroid carcinoma
thyroid carcinoma, mesenchymal stem cell, extracellular vesicle, GTF2I, FAT1, CDK4
Frontiers of Medicine
2023.17(6) 1186-1203
Immunometabolism: a new dimension in immunotherapy resistance
immune cell, immunometabolism, metabolic reprogramming, immunotherapy, resistance, tumor microenvironment, immune checkpoint inhibitor
Frontiers of Medicine
2023.17(4) 585-616
High frequency of alternative splicing variants of the oncogene in neuroendocrine tumors of the pancreas and breast
FAK
6/7
, SRRM4, neuroendocrine neoplasms, pancreas, breast
Frontiers of Medicine
2023.17(5) 907-923
Heterogeneity of the tumor immune microenvironment and clinical interventions
Heterogeneity tumor immune
Frontiers of Medicine
2023.17(4) 617-648
Progress and challenges in RET-targeted cancer therapy
pralsetinib, selpercatinib, RET-alteration, lung cancer, thyroid cancer, tumor-agnostic therapy, drug resistance
Frontiers of Medicine
2023.17(2) 207-219
Rare tumors: a blue ocean of investigation
rare tumors, diagnosis flowchart, treatment strategy, clinical trials recommendation
Frontiers of Medicine
2023.17(2) 220-230
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy
anti-CD19 chimeric antigen receptor T, immunotherapy, diffuse large B cell lymphoma, tumor microenvironment, tumor-associated macrophage, metabolism
Frontiers of Medicine
2023.17(4) 699-713
Prev
Next
Related search
Relevant information